Editorially reviewed · Last updated September 8, 2026 · How we review
Retatrutide News & Updates
This timeline separates reported trial results, company plans and regulatory decisions.
For background on the drug itself, see What Is Retatrutide (GLP-3)?. For a full trial tracker, see Clinical Trials & Results.
Upcoming Events to Watch
The main reported obesity readouts and ADA presentations are now past. The remaining milestones below are plans, not guaranteed results or approval dates.
| When | What | What is confirmed |
|---|---|---|
| November 14–17, 2026 | ObesityWeek in Washington, DC | Conference dates are confirmed; a retatrutide presentation should not be assumed without its programme. |
| Q1 2027 (company plan) | U.S. regulatory submission | Lilly plans a Biologics License Application; this is not FDA acceptance or approval. |
2026
August 12 — Lilly Announces Six Retatrutide Lawsuits
Lilly said it filed six lawsuits against U.S. sellers and asked online platforms, payment providers and regulators to act against unapproved retatrutide sales. These are the company’s announced actions and allegations, not findings that every defendant has been adjudicated liable. FDA separately states that retatrutide cannot lawfully be used in compounding under current federal law.
August 5 — Lilly Reiterates Q1 2027 Filing Plan
In its second-quarter update, Lilly said its clinical data package was complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain. It reiterated a planned U.S. Biologics License Application in the first quarter of 2027. A company filing plan does not establish FDA acceptance, approval timing or the eventual label.
July 23 — TRIUMPH-2 and TRIUMPH-3 Report; Lilly Names Q1 2027 as Its Filing Window
Lilly reported topline results from two more Phase 3 obesity trials on the same day, and for the first time named the quarter it intends to file in.
- TRIUMPH-2 (1,152 randomized; adults with type 2 diabetes and obesity or overweight) — average weight loss at 80 weeks of 12.7% (4 mg), 19.1% (9 mg) and 20.8% (12 mg) versus 4.0% on placebo, on the efficacy estimand. A1C fell 1.4% / 1.6% / 1.5% across the three doses from a 7.7% baseline, versus 0.2% on placebo.
- TRIUMPH-3 (1,949 randomized; adults with severe obesity and established cardiovascular disease) — average weight loss at 80 weeks of 21.6% (9 mg) and 22.6% (12 mg) versus 3.2% on placebo. In-study MACE hazard ratios were 0.82 (95% CI 0.55-1.22) for five-component MACE and 1.12 (95% CI 0.64-1.96) for three-component MACE — neither statistically significant, and the trial was not powered for cardiovascular outcomes.
- Regulatory: Lilly said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, superseding its earlier guidance of a 2026 submission.
Gastrointestinal adverse events were common in both trials. Discontinuation due to adverse events was 3.8% / 11.6% / 7.7% across the TRIUMPH-2 dose arms (4.9% on placebo) and 9.8% / 13.5% in TRIUMPH-3 (4.8% on placebo).
June 6 — ADA Results Cover Obesity, Diabetes, Sleep Apnea and Knee Pain
The TRIUMPH-1 sleep-apnea results included a 36.1-events-per-hour reduction in apnea–hypopnea index with 12 mg at 80 weeks under the efficacy estimand. This does not mean people should stop prescribed CPAP.
May 21 — TRIUMPH-1 Pivotal Obesity Results
March 19 — TRANSCEND-T2D-1 Topline Results
February 4 — Eli Lilly Q4 2025 Earnings: Retatrutide Filing Planned for 2026
January 30 — Lilly Announces $3.5 Billion Pennsylvania Plant for Retatrutide Production
Eli Lilly announced a $3.5 billion injectable medicine and device manufacturing facility in Fogelsville, Pennsylvania (Lehigh Valley). This is the fourth new U.S. plant in Lilly's expansion series and will specifically produce next-generation obesity injections including retatrutide.
- 850 permanent jobs, 2,000 construction jobs
- Construction was expected to start in 2026, with operation planned for 2031
- Brings total U.S. manufacturing commitments to over $50 billion since 2020
January 2026 — TRIUMPH Trial Design Paper Published
- TRIUMPH-1 and TRIUMPH-2 are basket trials with nested obstructive sleep apnea and osteoarthritis protocols
- TRIUMPH-3 evaluates weight management in a cardiovascular disease population
- Doses being tested: 4 mg (maintenance), 9 mg, and 12 mg
- Total enrollment across TRIUMPH: >5,800 participants
January 6 — Clarivate Includes Retatrutide in Its 2026 Drugs to Watch Report
Clarivate listed retatrutide among eleven therapies to watch. This was a commercial and pipeline assessment, not new trial evidence or a guarantee of future revenue.
2025
December 11 — TRIUMPH-4 Phase 3 Results: 28.7% Weight Loss (First Phase 3 Readout)
The defining retatrutide event of 2025. Eli Lilly announced topline results from TRIUMPH-4, the first Phase 3 trial to report data.
| Dose | Body Weight Change | Absolute Change |
|---|---|---|
| 12 mg | -28.7% | -71.2 lbs (-32.3 kg) |
| 9 mg | -26.4% | -64.2 lbs (-29.1 kg) |
| Placebo | -2.1% | — |
| Dose | Body Weight Change | Absolute Change |
|---|---|---|
| 12 mg | -23.7% | -60.0 lbs |
| 9 mg | -20.0% | -50.5 lbs |
- Discontinuation due to adverse events: 12.2% (9 mg), 18.2% (12 mg) vs. 4.0% (placebo)
- In patients with BMI >= 35 (84% of trial): discontinuation rates were 8.8% (9 mg), 12.1% (12 mg) vs. 4.8% (placebo) (a subgroup comparison that does not establish superior tolerability)
- Dysesthesia: 8.8% (9 mg), 20.9% (12 mg) vs. 0.7% (placebo) — sensory symptoms had also been reported in phase 2, so this was not their first appearance
- Some discontinuations attributed to "perceived excessive weight loss"
- Common GI side effects: nausea (38-43%), diarrhea (33-35%), constipation (22-25%), vomiting (~20%)
December 9 — Lilly Announces $6 Billion Alabama Manufacturing Facility
Two days before the TRIUMPH-4 data release, Lilly announced a $6 billion active pharmaceutical ingredient facility in Huntsville, Alabama — the largest initial investment in Alabama state history. The facility is planned to produce small-molecule synthetic and peptide medicines; the release specifically names orforglipron rather than establishing a retatrutide production allocation.
October 30 — Q3 2025 Earnings: Seven Phase 3 Readouts Confirmed for 2026
Lilly reported Q3 2025 revenue of $17.6 billion (+54% YoY). Regarding retatrutide:
- New Phase 3 trials initiated for chronic low back pain and overweight/obesity
- Seven Phase 3 readouts confirmed as expected in 2026
- R&D expenses of $3.47 billion (+27%) reflect the scale of the pipeline
June 22 — ADA 2025: Preclinical Comparison of Semaglutide, Tirzepatide, and Retatrutide
At the ADA 85th Scientific Sessions, a poster presentation compared the metabolic effects of semaglutide, tirzepatide, and retatrutide in a monogenic mouse model of obesity. This preclinical study added to the scientific understanding of retatrutide's differentiated triple-agonist mechanism.
June 2025 — Review Article: "Retatrutide — A Game Changer in Obesity Pharmacotherapy"
2025 Tirzepatide Compounding Litigation — Updated August 27, 2026
The Fifth Circuit affirmed the district court’s judgment upholding FDA’s tirzepatide shortage decision on August 27, 2026. That case concerned tirzepatide; it does not decide the rules for a future retatrutide launch. FDA separately states that retatrutide cannot currently be used in compounding under federal law.
February 26 — Lilly Announces $27 Billion U.S. Manufacturing Investment
Lilly announced plans to invest $27 billion across four new U.S. manufacturing sites. The Pennsylvania site later announced in January 2026 was explicitly linked to retatrutide. Total U.S. manufacturing commitments now exceed $50 billion since 2020.
February 21 — FDA Removes Semaglutide from Drug Shortage List
The FDA revised semaglutide's shortage categorization to "resolved," triggering the wind-down of compounding pharmacy access. FDA’s separate warning on unapproved GLP-1 products states that retatrutide and cagrilintide cannot currently be used in compounding under federal law.
February 6 — Q4 2024 Earnings: Lilly Accelerates Retatrutide Timeline
During the Q4 2024 earnings call, Lilly announced it expected to release late-stage data on retatrutide in 2025 — several months earlier than previously expected. The company confirmed TRIUMPH-4 results would be available later that year.
2024
June-July — MASLD Phase 2 Results Published in Nature Medicine
2023
- June 2023 — Phase 2 obesity results (24.2% weight loss at 48 weeks) published in NEJM
- 2023 — Phase 2 type 2 diabetes results published in The Lancet
- 2023 — TRIUMPH Phase 3 program launched
2022
- Phase 1 results published in The Lancet
Related Pages
- What Is Retatrutide (GLP-3)? — How the triple agonist works
- Clinical Trials & Results — Detailed TRIUMPH program tracker
- Retatrutide vs Mounjaro vs Ozempic — Side-by-side comparison
- Side Effects & Safety — What clinical trials have shown
- Cost & Access — Pricing, insurance, and how to get it
- retatrutide FDA approval timeline 2026–2028 — When retatrutide might be approved
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
- Lilly investor news
Eli Lilly
- STAT News
STAT
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
Retatrutide FDA Approval Timeline 2026-2028
Lilly plans a Q1 2027 BLA filing. TRIUMPH-1, -2 and -3 have reported. Approval window late 2027–28.
Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker
Trial results with population, endpoint, duration and source context. Use the trial finder for recruitment.
What Is Retatrutide (GLP-3)?
Eli Lilly’s investigational triple receptor agonist: how it works, what trials show, and why GLP-3 is an informal nickname.
TRANSCEND-T2D-1: Published Retatrutide Phase 3 Diabetes Results
Published Phase 3 diabetes results: 537 participants, 40 weeks, and distinct treatment-regimen and efficacy estimates.
TRIUMPH-3 Retatrutide Results: 22.6% at 12 mg
July 2026 topline results in adults with severe obesity and established cardiovascular disease, with weight, safety and event-data limitations.